Highlights

• The patent reveals that Leonurine improves NAFLD by regulating the PI3K-AKT-PPARα signaling pathway. Leonurine can also dose-dependently reduce hepatic lipid accumulation, inflammation, oxidative stress, cell apoptosis, and fibrosis, while restoring expression of key proteins such as PPARα, thereby improving lipid metabolism and liver pathology.
• This work supports the use of Leonurine as a natural compound for lipid regulation and liver protection, and opens new avenues for the application of traditional Chinese medicine in treating metabolic diseases.

Summary

This invention patent explores the mechanism and application potential of Leonurine in improving non-alcoholic fatty liver disease (NAFLD) and regulating liver lipid metabolism. By modulating the PI3K-AKT-PPARα signaling pathway, Leonurine exhibits multiple pharmacological effects, including lipid-lowering, anti-inflammatory, antioxidant, inhibition of hepatocyte apoptosis, and suppression of liver fibrosis.

The patent demonstrates that Leonurine significantly improves liver pathology in high-fat diet-induced rat models, reduces blood lipid levels, alleviates oxidative stress and inflammatory responses, and restores the expression of key proteins such as PPARα. Both in vivo and in vitro experiments confirm that its therapeutic effects are dose-dependent and closely related to the activation of PPARα and downstream effectors.

This patent provides a scientific basis for the development of Leonurine as a potential therapeutic agent for NAFLD and other lipid metabolism disorders.

朱依谆, 邱原野, “Application of Leonurine in Improving Non-Alcoholic Fatty Liver Disease (NAFLD) and Regulating Hepatic Lipid Metabolism,” China Patent CN114452277A, May 10, 2022.